Welcome to

The Interactive Pneumococcal Vaccination Model


  • Welcome
  • Background
  • The Model
  • Assumptions
  • Participants

This Interactive Pneumococcal Vaccination Model allows the health benefits, costs, and cost-effectiveness of pneumococcal vaccine to be projected according to an evidence-based approach. It is designed for users with familiarity using personal computers but with limited experience conducting health economic analyses. Wherever possible, the model is pre-populated with inputs drawn from the highest quality data sources.



If you'd like to register, please provide the following information.
You will receive an initial password via email.

Email Address:
Full Name:
Affiliation:
Desired Username [optional]:
  (default username will be your email address)

If you've forgotten your password, a new one can be emailed to you right now:
Registered Email Address:


For more information, please contact C. Greg Hagerty <cgreg@cgreg.com>
 

Additional Information


Background

Vaccination of children in developing countries against pneumococcal infection has great potential to save lives and reduce disability. The pneumococcus (Streptococcus pneumoniae) is the leading bacterial cause of acute lower respiratory infections, which in turn, are a major cause of child mortality. It also causes meningitis, other forms of invasive bacterial disease, and ear infections (acute otitis media).

Routine vaccination of infants against pneumococcus needs substantial investment by governments, non-governmental organizations, and donors.

Financial barriers to pneumococcal conjugate vaccine (PCV) have begun to fall. The GAVI Alliance decision to invest an initial $200 million to help a group of countries introduce pneumococcal conjugate and rotaviral vaccines was announced in November 2006, the same month that the International Finance Facility for Immunization issued its inaugural bonds. The announcement of an Advanced Market Commitment (AMC) of $1.5 billion for advancement of pneumococcal vaccines wasmade in February 2007. As pneumococcal conjugate vaccine becomes financially accessible, policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering how to spend healthcare dollars.

The Interactive Pneumococcal Vaccination Model addresses the need for streamlined cost-effectiveness analysis tools to assist decision makers in understanding the econdomic and health benefits associated with vaccine introductions.

The Model

This Interactive Pneumococcal Vaccination Model allows the health benefits, costs, and cost-effectiveness of pneumococcal vaccine to be projected according to an evidence-based approach. It is designed for users with familiarity using personal computers but with limited experience conducting health economic analyses. Wherever possible, the model is pre-populated with inputs drawn from the highest quality data sources. The model combines the results from three recent international efforts to assess the burden of pneumococcal disease and to develop standards for assessing the cost-effectiveness of health prevention:

WHO - Choosing Interventions that are Cost-Effective (WHO-CHOICE): WHO-CHOICE has assembled country-level data on the direct medical costs associated with hospital and outpatient management of diseases.

Global Serotype Project: Collecting unpublished and published sources of pneumococcal serotype data from across the globe, the GSP investigators have developed contemporary estimates of the regional proportions of disease-causing pneumococcal isolates covered by pneumococcal conjugate vaccines in children under age five.

WHO- Hib and Pneumococcal Global Disease Burden Project: The project investigators modeled credible country-level estimates of Haemophilus influenzae type B and pneumococcal disease burden in children under five, in order to understand the importance of disease due to these bacterial pathogens and the potential for control through vaccination.

Assumptions

  1. The tool will not be used for commercial purposes, for nonprofit use only, available without charge.
  2. Users take responsibility for all modifications made to the pre-populated model inputs. Using expert guidance, the tool has been pre-populated with the evidence from high quality, recognized sources. Users who choose to modify model inputs should seek their own expert guidance in identifying high quality and unbiased sources of information.
  3. Limited technical support is available. However, the model is intended to be freestanding. We encourage users to seek local sources of expertise in using the tool. Questions regarding technical problems can be addressed to the PneumoADIP and development teams.

Expert Review Panel and Participants

The Interactive Pneumococcal Vaccination Model was developed through an expert panel process. The panel reached consensus on the key assumptions about epidemiology, vaccine efficacy, costs and model outputs projecting the cost-effectiveness of pneumococcal conjugate vaccine for infants in GAVI-eligible countries. Members of the panel were chosen for their expertise in pneumococcal epidemiology, vaccine-related health economics, public health, or preventive medicine in GAVI-eligible settings.

Expert Panelists

Dagna Constenla, PhD
Economic consultant
Fort Collins, CO, USA
Felicity Cutts, PhD
Professor Emeritus
Infectious Disease Epidemiology Unit
London School of Hygiene and Tropical Medicine
Provence, France
Adam Finn, MD
David Baum Professor of Paediatrics;
Head, Unit of Child Health,
Dept. Clinical Sciences at South Bristol
Institute of Child Life & Health, University of Bristol
Bristol, UK
Andrew Pollard, MD
Reader in Paediatric Infection and Immunity;
Consultant in Charge of the Oxford Vaccine Group;
Head of the Paediatric Infection and Immunity Laboratory
Department of Paediatrics, University of Oxford
John Radcliffe Hospital
Oxford, UK
G. Tom Ray, MBA
Senior Analyst
Division of Research
Kaiser Permanente
Oakland, CA, USA
Cyndy Whitney, MD MPH
Acting Chief
Respiratory Diseases Branch, National Center for Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA, USA

GAVI's PneumoADIP Team

http://www.preventpneumo.org
Rabia Akram MPH, MBA
Research Project Manager
Julie Buss, MPH
Communications Manager
Michelle Moncrieffe-Foreman
Communications Manager
H. Benedicta Kim
Manager, Communications Team
Maria Deloira Knoll, PhD
Director of Research
Orin Levine, PhD
Executive Director
Farzana Muhib, MPH MALD
Research Project Coordinator, Research Team
Kate O'Brien MD, MPH
Deputy Director of Research

Investigators/Development Team

C. Greg Hagerty, PhD
Assistant Professor of Medicine
UMDNJ - Robert Wood Johnson Medical School
New Brunswick, NJ USA
cgreg@cgreg.com
Anushua Sinha, MD MPH
Assistant Professor of Preventive Medicine and Community Health
UMDNJ - New Jersey Medical School
Newark, NJ USA
Frank Sonnenberg, MD
Professor of Medicine, Associate Director of Clinical Informatics
UMDNJ - Robert Wood Johnson Medical School
New Brunswick, NJ USA

The Pneumococcal vaccines Accelerated Development and Introduction Plan is based
at Johns Hopkins Bloomberg School of Public Health and is funded by GAVI Alliance.